3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
30
Neoplasm Metastasis
10
Carcinoma, Non-Small-Cell Lung
8
Stomach Neoplasms
7
Neoplasms
6
Colorectal Neoplasms
6
Adenocarcinoma
6
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Endometrial Neoplasms
3
Advanced Solid Tumor
3
Triple Negative Breast Neoplasms
2
Sarcoma
2
Prostatic Neoplasms
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Renal Cell
2
Brain Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Unresectable Locally Recurrent Breast Cancer
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Solid Cancer
1
Interventions
Gemcitabine
12
Cisplatin
10
pembrolizumab
7
Fluorouracil
7
Leucovorin
6
Oxaliplatin
5
durvalumab
3
Capecitabine
3
zanidatamab
2
Paclitaxel
2
Irinotecan
2
Folfox protocol
2
Bevacizumab
2
vandetanib
1
tucatinib
1
trastuzumab deruxtecan
1
seribantumab
1
merestinib
1
lenvatinib
1
irinotecan sucrosofate
1
galactomannan
1
fludarabine
1
exatecan
1
bintrafusp alfa protein, human
1
becatecarin
1
aldesleukin
1
Trastuzumab
1
Temozolomide
1
Tegafur
1
S 1 (combination)
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Gallbladder Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled